Gabather AB receives initial EEG data analysis from the GT-002 target engagement study
Gabather AB ( www.gabather.com) has received the electroencephalography (EEG) analysis of the 17 human healthy volunteers involved in the target engagement study with the lead clinical candidate GT-002 as part of the collaboration with MINDIG (https://mindig.io/company/). The quantitative analysis of the recordings showed statistically significant increase induced by GT-002 on the EEG alpha frequency band power. MINDIG will continue the EEG data analysis and expects to deliver new analysis of the data early next year.
“ The EEG data analysis shows that our drug candidate GT-002 , when given orally, modifies the brain activity in a specific manner distinct from competitor compounds and generates a selective brain activity modulation specific for GT-002. This enables us to explore new indications for GT-002 in mental health - what a great way to end the year -and we look forward to patient studies in 2024” says Michael Robin Witt, CEO of Gabather.
Contact Information
Michael-Robin Witt, CEO
Phone: 073-687 28 39
E-mail: [email protected]
About Gabather
Gabather is a clinical-stage pharmaceutical company aiming to transform the treatment of neuropsychiatric disorders. The Company was founded as a response to the significant unmet need and lack of innovative therapeutics in the mental health treatment landscape. Gabather is dedicated to developing innovative therapeutics for the treatment of a broad range of neuropsychiatric disorders. The goal is to accelerate the development of new groundbreaking medicines to achieve clinically meaningful therapies for the patients.
For more information, please visit: www.gabather.com
Certified Adviser
Corpura Fondkommission AB
Phone: +4672-252 34 51
Email: [email protected]
www.corpura.se
